Key result
APOB18 overexpression reduces atherosclerosis in mice by curbing endothelial lipoprotein transport.
The N-terminal region of APOB mediates atherogenic lipoprotein interaction with endothelial cells, and its blockade reduces atherosclerosis in preclinical models.
Apolipoprotein B (APOB) containing lipoproteins contribute to atherosclerosis by entering the arterial wall through the endothelial cell (EC) surface receptors scavenger receptor-BI (SR-BI) and activin receptor-like kinase 1 (ALK1). We used N-terminal fragments of APOB, molecular modeling, and site-directed mutagenesis to identify and block the binding of chylomicrons and LDL to these receptors in cells and mice. We discovered that different APOB regions interact with SR-BI and ALK1 expressed on ECs APOB48 lipoproteins were only internalized by SR-BI. A fragment of APOB, comprising 18% of the N-terminal sequence, APOB18, reduced the uptake and transport of both chylomicrons and LDL by ECs, whereas a shorter fragment, APOB12, only blocked ALK1 mediated uptake of APOB100 containing lipoproteins. Importantly, overexpressing APOB18 decreased atherosclerosis in hypercholesterolemic mice. These findings identify the N-terminal region of APOB as the cause of atherosclerosis and illustrate an approach to treating or preventing vascular disease.
No takes yet. Share an insight, caveat, or question.
Cabodevilla et al. (2026) studied Atherosclerosis. APOB18 overexpression was evaluated on Atherosclerosis development. Overexpressing the APOB18 fragment decreased atherosclerosis in hypercholesterolemic mice by reducing the uptake and transport of atherogenic lipoproteins by endothelial cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: